A detailed history of Perceptive Advisors LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Perceptive Advisors LLC holds 724,698 shares of CRNX stock, worth $39.1 Million. This represents 0.97% of its overall portfolio holdings.

Number of Shares
724,698
Previous 1,476,203 50.91%
Holding current value
$39.1 Million
Previous $66.1 Million 44.01%
% of portfolio
0.97%
Previous 1.91%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$43.83 - $54.98 $32.9 Million - $41.3 Million
-751,505 Reduced 50.91%
724,698 $37 Million
Q1 2024

May 15, 2024

BUY
$34.76 - $46.81 $7.67 Million - $10.3 Million
220,691 Added 17.58%
1,476,203 $69.1 Million
Q4 2023

Feb 14, 2024

SELL
$25.62 - $37.07 $210,596 - $304,715
-8,220 Reduced 0.65%
1,255,512 $44.7 Million
Q3 2023

Nov 14, 2023

SELL
$15.97 - $30.59 $10.9 Million - $20.9 Million
-683,205 Reduced 35.09%
1,263,732 $37.6 Million
Q2 2023

Aug 14, 2023

SELL
$15.73 - $23.6 $25.3 Million - $37.9 Million
-1,607,950 Reduced 45.23%
1,946,937 $35.1 Million
Q1 2023

May 15, 2023

SELL
$15.31 - $21.1 $7.42 Million - $10.2 Million
-484,389 Reduced 11.99%
3,554,887 $57.1 Million
Q4 2022

Feb 14, 2023

SELL
$15.49 - $19.05 $19.9 Million - $24.4 Million
-1,281,756 Reduced 24.09%
4,039,276 $73.9 Million
Q2 2022

Aug 15, 2022

BUY
$16.49 - $27.64 $2.6 Million - $4.35 Million
157,515 Added 3.05%
5,321,032 $99.2 Million
Q4 2021

Feb 14, 2022

BUY
$19.35 - $28.41 $23.2 Million - $34.1 Million
1,200,000 Added 30.28%
5,163,517 $147 Million
Q2 2021

Aug 16, 2021

BUY
$15.9 - $21.15 $4.84 Million - $6.43 Million
304,136 Added 8.31%
3,963,517 $74.7 Million
Q2 2020

Aug 14, 2020

BUY
$13.04 - $23.23 $14 Million - $24.9 Million
1,071,428 Added 41.4%
3,659,381 $59.2 Million
Q3 2018

Nov 14, 2018

BUY
$22.66 - $36.8 $58.6 Million - $95.2 Million
2,587,953 New
2,587,953 $74.1 Million

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.9B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Perceptive Advisors LLC Portfolio

Follow Perceptive Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perceptive Advisors LLC with notifications on news.